NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Forecast, Price & News $16.41 -0.01 (-0.06%) (As of 05:23 PM ET) Add Compare Share Share Today's Range$16.12▼$16.8150-Day Range$15.65▼$22.8952-Week Range$14.51▼$29.14Volume455,598 shsAverage Volume1.45 million shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/APrice Target$29.85 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Travere Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside83.9% Upside$29.85 Price TargetShort InterestBearish10.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 5 Articles This WeekInsider TradingSelling Shares$29,478 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.63) to ($3.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector414th out of 1,009 stocksPharmaceutical Preparations Industry195th out of 494 stocks 3.4 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.85, Travere Therapeutics has a forecasted upside of 83.9% from its current price of $16.23.Amount of Analyst CoverageTravere Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.11% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 4.07%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 3.3 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,478.00 in company stock.Percentage Held by InsidersOnly 4.71% of the stock of Travere Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($4.63) to ($3.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 24.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Travere Therapeutics (NASDAQ:TVTX) StockTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.Read More Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Stock News HeadlinesMay 29, 2023 | seekingalpha.comTravere: Turbulent Journey With FILSPARI, Downgrading To SellMay 24, 2023 | americanbankingnews.comTD Cowen Initiates Coverage on Travere Therapeutics (NASDAQ:TVTX)May 30, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 22, 2023 | msn.comTD Cowen Initiates Coverage of Travere Therapeutics (TVTX) with Outperform RecommendationMay 22, 2023 | markets.businessinsider.com11 Analysts Have This to Say About Travere TherapeuticsMay 16, 2023 | msn.comChinook Therapeutics down 5% following Muddy Waters short reportMay 16, 2023 | finance.yahoo.comIs There An Opportunity With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 44% Undervaluation?May 14, 2023 | americanbankingnews.comElizabeth E. Reed Sells 825 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockMay 30, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 13, 2023 | americanbankingnews.comAnalysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Target Price at $31.00May 6, 2023 | americanbankingnews.comFY2024 Earnings Forecast for Travere Therapeutics, Inc. (NASDAQ:TVTX) Issued By WedbushMay 6, 2023 | americanbankingnews.comBrokers Issue Forecasts for Travere Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TVTX)May 6, 2023 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Expected to Earn FY2024 Earnings of ($3.14) Per ShareMay 6, 2023 | americanbankingnews.comTravere Therapeutics, Inc. to Post FY2024 Earnings of ($3.21) Per Share, Wedbush Forecasts (NASDAQ:TVTX)May 5, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Lifted to Neutral at Bryan, Garnier & CoMay 5, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) PT Lowered to $22.00May 5, 2023 | americanbankingnews.comEvercore ISI Cuts Travere Therapeutics (NASDAQ:TVTX) Price Target to $26.00May 4, 2023 | msn.comTravere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue EstimatesMay 4, 2023 | msn.comRecap: Travere Therapeutics Q1 EarningsMay 4, 2023 | finance.yahoo.comTravere Therapeutics Reports First Quarter 2023 Financial ResultsMay 4, 2023 | americanbankingnews.comAnalysts Issue Forecasts for Travere Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:TVTX)May 3, 2023 | msn.comHC Wainwright & Co. Maintains Travere Therapeutics (TVTX) Buy RecommendationMay 3, 2023 | americanbankingnews.comTravere Therapeutics (TVTX) Set to Announce Earnings on ThursdayMay 3, 2023 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Given New $23.00 Price Target at GuggenheimMay 2, 2023 | msn.comWells Fargo Maintains Travere Therapeutics (TVTX) Overweight RecommendationMay 2, 2023 | msn.comB of A Securities Maintains Travere Therapeutics (TVTX) Buy RecommendationMay 2, 2023 | markets.businessinsider.comWells Fargo Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Company Calendar Last Earnings10/28/2021Today5/30/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees310Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.85 High Stock Price Forecast$42.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+81.9%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-278,480,000.00 Net Margins-130.98% Pretax Margin-130.83% Return on Equity-236.09% Return on Assets-38.69% Debt Debt-to-Equity Ratio1.99 Current Ratio4.63 Quick Ratio4.58 Sales & Book Value Annual Sales$212.02 million Price / Sales5.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book24.49Miscellaneous Outstanding Shares74,610,000Free Float71,094,000Market Cap$1.22 billion OptionableOptionable Beta0.46 Key ExecutivesEric M. DubePresident, Chief Executive Officer & DirectorChris ClineChief Financial OfficerBill RoteSenior VP, Head-Research & DevelopmentJula InrigChief Medical OfficerElizabeth E. ReedSecretary, Senior Vice President & General CounselKey CompetitorsPliant TherapeuticsNASDAQ:PLRXArvinasNASDAQ:ARVNIDEAYA BiosciencesNASDAQ:IDYACatalyst PharmaceuticalsNASDAQ:CPRXMannKindNASDAQ:MNKDView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,495 shares on 5/26/2023Ownership: 0.016%Ameriprise Financial Inc.Bought 90,883 shares on 5/22/2023Ownership: 0.429%International Biotechnology Trust PLCSold 238,000 shares on 5/18/2023Ownership: 0.189%New York State Common Retirement FundBought 1,780 shares on 5/18/2023Ownership: 0.080%Thrivent Financial for LutheransBought 95,562 shares on 5/17/2023Ownership: 0.353%View All Insider TransactionsView All Institutional Transactions TVTX Stock - Frequently Asked Questions Should I buy or sell Travere Therapeutics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TVTX shares. View TVTX analyst ratings or view top-rated stocks. What is Travere Therapeutics' stock price forecast for 2023? 11 Wall Street research analysts have issued 12 month price targets for Travere Therapeutics' shares. Their TVTX share price forecasts range from $17.00 to $42.00. On average, they predict the company's share price to reach $29.85 in the next year. This suggests a possible upside of 81.9% from the stock's current price. View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts. How have TVTX shares performed in 2023? Travere Therapeutics' stock was trading at $21.03 at the beginning of the year. Since then, TVTX stock has decreased by 22.0% and is now trading at $16.41. View the best growth stocks for 2023 here. When is Travere Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our TVTX earnings forecast. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) released its quarterly earnings data on Thursday, October, 28th. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.13. The company had revenue of $68.20 million for the quarter, compared to analysts' expectations of $60.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 236.09% and a negative net margin of 130.98%. Travere Therapeutics's revenue for the quarter was up 33.5% on a year-over-year basis. During the same period last year, the firm posted ($0.44) EPS. What ETFs hold Travere Therapeutics' stock? ETFs with the largest weight of Travere Therapeutics (NASDAQ:TVTX) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) and iShares Biotechnology ETF (IBB). What is Travere Therapeutics' stock symbol? Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX." Who are Travere Therapeutics' major shareholders? Travere Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.58%), State Street Corp (5.85%), Macquarie Group Ltd. (4.89%), Renaissance Technologies LLC (2.87%), Assenagon Asset Management S.A. (2.23%) and Pictet Asset Management SA (2.08%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Travere Therapeutics' stock price today? One share of TVTX stock can currently be purchased for approximately $16.41. How much money does Travere Therapeutics make? Travere Therapeutics (NASDAQ:TVTX) has a market capitalization of $1.22 billion and generates $212.02 million in revenue each year. The company earns $-278,480,000.00 in net income (profit) each year or ($4.44) on an earnings per share basis. How many employees does Travere Therapeutics have? The company employs 310 workers across the globe. How can I contact Travere Therapeutics? Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The company can be reached via phone at (888) 969-7879, via email at ir@retrophin.com, or via fax at 302-645-1280. This page (NASDAQ:TVTX) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.